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Which medications can be split
without compromising efficacy 
and safety?
z Evidence summary
Few studies have looked at the clinical
effects of pill-splitting. A randomized trial
(n=29) evaluated tablet-splitting by patients
taking lisinopril for hypertension.1 Patients
were randomized to split tablets or whole
tablets for 2 weeks, then crossed over to the
other group for 2 weeks. There was no dif-
ference in blood pressures between groups. 
A retrospective study of simvastatin
evaluated 1098 patients taking whole
tablets and 1098 patients converted to
split tablets of the same dose.2 There was
no difference in average final low-density
lipoprotein (LDL) cholesterol (111 ± 30
mg/dL vs 112 ± 32 mg/dL) or mean ala-
nine aminotransferase (ALT) level. 
Another retrospective study evaluated
Split tablets of lisinopril are as effective as
whole tablets of the same dose for 
hypertension (SOR: B, based on small 
randomized crossover study). Similarly,
split tablets of atorvastatin, lovastatin, and 
simvastatin are no less effective for lowering
cholesterol (SOR: B, based on retrospective
cohort studies). Extended-release, enteric-
coated, or tablets that cannot be split 
accurately are not appropriate for splitting
(SOR: C, based on observational studies);
the accuracy of splitting also depends 
on device used and user skill (SOR: C,
based on observational study) (TABLE).
Splitting scored tablets is efficacious and
safe, but cost savings are often limited
The theoretical benefit of tablet-splitting is
reduced prescription cost. Splitting scored
tablets is already FDA-approved as safe
and efficacious. However, the cost savings
garnered by splitting these types of tablets
is often limited. The biggest savings comes
from splitting flat-priced tablets (costs of
different dosage strengths are equal/
similar), but these tablets are not usually
scored. Splitting unscored tablets is 
considered “off-label” because each split
tablet dose may not have equal drug
strength. However, splitting drugs with a
long half-life and wide therapeutic index—
such as those used to treat chronic 
asymptomatic conditions like hypertension
or dyslipidemia—should pose minimal risk.
Be aware that recommending tablet-split-
ting to insured patients solely to spare them
a copay—instructing a patient to take a half
tablet to make a 30-day paid prescription
cover 60 days—may be considered insur-
ance fraud. However, this is not an issue for
patients without prescription coverage.
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tablet-splitting by 512 patients taking
statins (atorvastatin, lovastatin, simvas-
tatin).3 Cholesterol values after 12 or more
weeks on a stable whole-tablet dose were
compared with those 6 to 52 weeks after
initiating tablet-splitting; no significant
change was seen in total cholesterol or
triglycerides. There was a statistically sig-
nificant decrease in LDL (102 ± 28 vs 97 ±
29 mg/dL, P<.001), an increase in high-
density lipoprotein (HDL) cholesterol (46 ±
12 vs 48 ± 12 mg/dL, P<.001), and an
increase in aspartate aminotransferase
(AST) (26 ± 8 vs 28 ± 10 units/L, P<.001),
which was attributed to higher medication
dosage from accidental ingestion of whole
tablets and to diet and lifestyle modifica-
tions. Another retrospective evaluation of
109 patients with split atorvastatin or sim-
vastatin found no significant difference in
total cholesterol or LDL values after initiat-
ing the tablet-splitting program.4
Thirty patients aged 50 years or older,
half of whom received instruction and a
demonstration, evaluated 2 tablet-splitters
with different blade positions and types of
guide.5 One device (Apex Pill Splitter) pro-
duced more accurate results by 10% to
20% (P value not provided) with meto-
prolol, warfarin, and lisinopril tablets.
Instructed patients were 1% to 10% more
accurate, as were those with experience
splitting warfarin tablets (P=.003). 
In another study, 94 healthy volunteers
(mean age, 46.2 years) each split 10
hydrochlorothiazide 25 mg tablets by
hand. Forty-one percent of the split prod-
ucts were more than 10% off ideal weight;
12% of tablets were more than 20% off.6
Manufacturing regulations require that
medication doses vary by less than 10% of
the nominal dose. Another study using 
5 medications found that 0% to 44% of
split tablets deviated from ideal weight by
20%, depending on tablet shape.7
Surveys of patient acceptance of tablet-
splitting report varied rates (3%–74%),3,6
In 1 study,1 89% and 97% said they would
split tablets to save money for themselves or
their health facility, respectively.
Experts recommend assessing patients
for their physical (dexterity, strength, visual
acuity) and cognitive ability to split tablets,
as well as whether doing so saves money.8
Recommendations from others
The American Medical Society and
American Pharmacists Association oppose
mandatory tablet-splitting and recommend
against splitting tablets that are modified-
release, combination products, unscored,
film-coated, friable, or dose-critical. 
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The cost savings
of splitting scored
tablets is limited;
but splitting
unscored tablets 
is “off-label”
because the splits
may be unequal
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If you answer “NO” to any of these questions, reconsider the 
appropriateness of recommending tablet-splitting to a patient
Medication characteristics
—Is the tablet scored*?
—Is the tablet modified or extended release?
—Is the tablet a combination product?
—Is the tablet a critical dose product?
—Does the tablet crumble when split?
—Is the tablet film-coated or otherwise modified to mask taste or for 
some other reason?
*Some tablets without scoring may be split easily 
with tablet-splitting device.
Patient characteristics
—Is the patient physically capable of splitting the tablet 
(consider dexterity, strength, and visual acuity)? 
—Will the patient’s medication regimen remain manageable with tablet-
splitting (in other words, will tablet-splitting make patient’s regimen 
excessively complicated)? 
Questions to consider before tablet-splitting
 
